Archives: In the News Items

Inflammatory bowel disease and other chronic inflammatory diseases remain challenging to treat, in part because durable benefit may require more than suppression of pro-inflammatory signaling alone. Emerging biology suggests that salt-inducible kinase 2 (SIK2) sits at a key node of innate immune activation and tissue repair, making it an attractive target for diseases such as ulcerative colitis.

A single, optimized LLM unifies what previously required multiple models and can serve as a reasoning partner for medical chemists.

Nimbus, an artificial-intelligence drug-discovery company, says that it is eligible for upfront and near-term milestone payments totaling $55 million

The Boston AI biotech is going to work with the pharma giant to develop a new oral drug for obesity, joining the spate of deals and fundraisings that continue to target new obesity medicines.